The SurVaxM vaccine for glioblastoma
Developed here at Roswell Park, SurVaxM, is a type of immunotherapy for glioblastoma, an aggressive type of malignant brain tumor. SurVaxM has shown positive results in early-phase clinical trials and large, multicenter studies are beginning. For information about enrolling in this clinical trial, please call 1-800-ROSWELL (1-800-767-9355).
The need for new and better brain tumor treatments remains urgent. Through our clinical trials program, we can offer eligible patients access to treatments that might not be available to them at other centers.
A clinical trial is a research study designed to evaluate a promising new medical treatment. It could involve a new way of preventing, diagnosing and/or treating cancer. Clinical trials may focus on:
- New ways of preventing cancer with drugs, diet and/or exercise
- New ways to better diagnose cancer
- New drugs to treat cancer
- New ways to use existing treatments, such as surgery or radiation therapy
- New ways to improve quality of life for patients with cancer
When the information from a clinical trial shows that the treatment being studied is more effective than standard treatments, it becomes the new standard of care.
Every treatment that is now FDA-approved began as a treatment being studied in a clinical trial. Patients who enrolled in that clinical trial had access to that treatment before it was FDA-approved and widely available.